Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling

Blood

Volumn 116, Issue 6, 2010, Pages 953-961

  Hartmann, Elena M ^a   Campo, Elias ^b   Wright, George ^c   Lenz, Georg ^d   Salaverria, Itziar ^b,e   Jares, Pedro ^b   Xiao, Wenming ^f   Braziel, Rita M ^g   Rimsza, Lisa M ^h   Chan, Wing Chung ⁱ   Weisenburger, Dennis D ⁱ   Delabie, Jan ^j   Jaffe, Elaine S ^c   Gascoyne, Randy D ^k   Dave, Sandeep S ^l   Mueller Hermelink, Hans Konrad ^a   Staudt, Louis M ^c   Ott, German ^m   Beà, Sílvia ^b   Rosenwald, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m ROBERT BOSCH HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956540011     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-263806     Document Type: Article

References (45)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
2. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-762. (Pubitemid 47463673)
3. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-197.
4. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981.
5. Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34(10):1030-1034. (Pubitemid 37315255)
6. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol. 2007;25(10):1216-1222.
7. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 1999;93(12):4365-4374. (Pubitemid 29279280)
8. Tagawa H, Karnan S, Suzuki R, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 2005;24(8):1348-1358. (Pubitemid 40343115)
9. de Leeuw RJ, Davies JJ, Rosenwald A, et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet. 2004;13(17):1827-1837. (Pubitemid 39214331)
10. Kohlhammer H, Schwaenen C, Wessendorf S, et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood. 2004;104(3):795-801. (Pubitemid 38970576)
11. Schraders M, Jares P, Bea S, et al. Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. Br J Haematol. 2008;143(2):210-221.
12. Vater I, Wagner F, Kreuz M, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol. 2009;144(3):317-331.
13. Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 2009;113(13):3059- 3069.
14. Kawamata N, Ogawa S, Gueller S, et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol. 2009;37(8):937-946.
15. Nielaender I, Martin-Subero JI, Wagner F, Martinez-Climent JA, Siebert R. Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia. 2006;20(5):904-905.
16. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
17. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315-4321. (Pubitemid 41775942)
18. Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007;109(3):1202-1210. (Pubitemid 46220669)
19. Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2006;103(7):2352-2357.
20. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105(11):4445-4454. (Pubitemid 40720793)
21. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A. 2000;97(6):2773-2778. (Pubitemid 30159247)
22. Katzenberger T, Kienle D, Stilgenbauer S, et al. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol. 2008;142(4):538-550. (Pubitemid 352020198)
23. Sander S, Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization: incidence and clinicopathological correlations. Haematologica. 2008;93(5):680-687. (Pubitemid 351669307)
24. Marce S, Balague O, Colomo L, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res. 2006;12(12):3754-3761. (Pubitemid 44000257)
25. Laerm A, Helmbold P, Goldberg M, et al. Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the biliary system. J Hepatol. 2007;46(1):89-97. (Pubitemid 44834428)
26. Shimoda M, Takahashi M, Yoshimoto T, et al. A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin Cancer Res. 2006;12(20):6005-6011. (Pubitemid 44703761)
27. Nagai H, Li Y, Hatano S, et al. Mutations and aberrant DNA methylation of the PROX1 gene in hematologic malignancies. Genes Chromosomes Cancer. 2003;38(1):13-21. (Pubitemid 36994880)
28. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109(1):271-280. (Pubitemid 46053067)
29. Flordal Thelander E, Ichimura K, Collins VP, et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res. 2007;31(9):1219-1230. (Pubitemid 46873737)
30. Bentz M, Plesch A, Bullinger L, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2000;27(3):285-294. (Pubitemid 30067458)
31. Allen JE, Hough RE, Goepel JR, et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol. 2002;116(2):291-298.
32. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132(3):303-316. (Pubitemid 43381537)
33. Higa LA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol. 2003;5(11):1008-1015. (Pubitemid 37406915)
34. Kotake Y, Zeng Y, Xiong Y. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res. 2009;69(5):1809-1814.
35. Garkavtsev I, Grigorian IA, Ossovskaya VS, et al. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature. 1998;391(6664):295-298. (Pubitemid 28099018)
36. Nouman GS, Anderson JJ, Lunec J, Angus B. The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol. 2003;56(7):491-496. (Pubitemid 36819419)
37. Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell. 2005;97(1):87-96.
38. Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112(7):1471-1479. (Pubitemid 351441159)
39. Kobel M, Xu H, Bourne PA, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009;22(3):469-475.
40. Blenk S, Engelmann JC, Pinkert S, et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer. 2008;8:106 (Pubitemid 351998115)
41. Martinez-Climent JA, Vizcarra E, Sanchez D, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood. 2001;98(12):3479-3482.
42. Rai R, Dai H, Multani AS, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006;10(2):145-157. (Pubitemid 44175904)
43. Yang SZ, Lin FT, Lin WC. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008;9(9):907-915.
44. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008;20(6):638-646.
45. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 2008;13(3):188-192. (Pubitemid 351318373)